Login to Your Account



Acacia Pursuing Late-Stage Plans, Partner for PONV Drug

By Nuala Moran
Staff Writer

Wednesday, June 6, 2012

LONDON – Acacia Pharma Ltd. reported positive results in a Phase II study of ADP421 in the prevention of postoperative nausea and vomiting (PONV) and is now progressing the compound to Phase III, as it mulls the commercialization strategy.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription